Post on 26-Apr-2020
transcript
224 References
REFERENCES
1. Alexander S, Juergen S, Bodmeier R. Gastroretentive drug delivery systems.
Expert Opin. Drug Deliv. 3(2), 2006, 217-233.
2. Hirtz J. The GIT absorption of drugs in man: A review of current concepts and
methods of investigation. Br J Clin Pharmacol. 19, 1985, 77S-83S.
3. Ponchel G, Irache JM. Specific and non-specific bioadhesive particulate system
for oral delivery to the gastrointestinal tract. Adv Drug Del Rev. 34, 1998, 191-
219.
4. Deshpande AA, Shah NH, Rhodes CT, Malick W. Development of a novel
controlled-release system for gastric retention. Pharm Res. 14, 1997, 815-819.
5. Rednick AB, Tucker SJ. Sustained release bolus for animal husbandry. US
patent 3 507 952. April 22, 1970.
6. Urguhart J, Theeuwes F. Drug delivery system comprising a reservoir
containing a plurality of tiny pills. US patent 4 434 153. February 28, 1994.
7. Kedzierewicz F, Thouvenot P, Lemut J, Etienne A, Hoffman M, Maincent P.
Evaluation of peroral silicone dosage forms in humans by gamma-scintigraphy.
J Control Release. 58, 1999, 195-205.
8. Groning R, Heun G. Dosage forms with controlled gastrointestinal passage—
studies on the absorption of nitrofurantion. Int J Pharm. 56, 1989, 111-116.
9. Standley S. Davis. Formulation strategies for absorption window. DDT. 10(4),
2005, 249-257.
10. Hoffman A and Strepensky D. Pharmacodynamic aspects of modes of drug
administration for optimization of drug therapy, Crit Rev Ther Drug Carrier
Syst, 16, 1999, 571-639.
225 References
11. Hejazi R and Amiji M. Stomach specific anti H.pylori therapy. I: preparation
and characterization of tetracycline of a floating multiple-unit capsule, a high-
density loaded chitosan microspheres, Int J Pharm, 235, 2002, 87-94.
12. Dave BS, Amin AF and Patel M. Gastroretentive drug delivery system of
Ranitidine HCl formulation and In vitro evaluation. AAPS Pharm Sci Tech, 5,
2004, 1-10.
13. Sawicki W. Pharmacokinetics of verapamil and nor verapamil from controlled
release floating pellets in humans. Eur J Pharm Biopharm, 53, 2002, 29-35.
14. Davis SS et al., Transit of pharmaceutical dosage forms through the small
intestine, Gut 27, 1986, 886-892.
15. Desai S, A Novel Floating Controlled Release Drug Delivery System Based on a
Dried Gel Matrix Network, [master’s thesis]. 1984 Jamaica, NY, St John’s
University.
16. Vantrappen G R, Peeters T L, Janssens J. The secretory component of
interdigestive migratory motor complex in man, Scand J Gastroenterol. 14,
1979, 663-667.
17. Pooja Mathur, Kamal Saroha, et al., Floating drug delivery system: An
innovative acceptable approach in gastroretentive drug delivery, Archives of
Applied Science Research, 2 (2), 2010, 257-270.
18. Desai S, Bolton SA. A floating controlled release drug delivery system: In vitro-
In vivo evaluation, Pharm Res, 10, 1993, 1321-1325.
19. Wilson CG and Washington N. Review: Physiological Pharmaceutics: Barriers
to Drug Absorption, 2nd
edn. Chichester: Ellis Horwood, 2001, 47.
226 References
20. Rubinstein A, Gruber VH, Robinson JR. In oral sustained release formulations:
Design and evaluation, edited by A Yacobi and E Halperin-Walega (Pergamon
Press, New York) 1988, 125-126.
21. SH. Shaha, JK. Patel, K.Pundarikakshdu, N.V. Patel. An overview of a gastric-
retentive floating drug delivery system, Asian Journal of Pharmaceutical
Sciences 4(1), 2009, 65-80.
22. Park HM, Chernish SM, Rosenek BD, et al. Gastric emptying of enteric-coated
tablets. Dig Dis Sci 29, 1984, 207-12.
23. Meyer JH, Dressman J, Fink A and Amidon G. Effect of size and density on
canine gastric emptying of nondigestible solids. Gastroent. 89(4), 1985, 805-13.
24. Jose Gutierrez-Rocca, Hossein Omidian and Khalid Shah, Progress in
Gastroretentive Drug Delivery Systems, Pharmatech, 2003, 152.
25. A.K. Hilton, P.B. Daisy, In vitro and In vivo evaluation of an oral sustained-
release floating dosage form of amoxycillin trihydrate, Int. J. Pharm. 86, 1992
79–88.
26. P.R. Sheth, J.L. Tossounian, Sustained release pharmaceutical capsules, US
Patent 4, November 21, 1978, 126, 672.
27. Harrigan RM. Drug delivery device for preventing contact of undissolved drug
with the stomach lining, US Patent 4, October 25, 1977, 055, 178.
28. Whitehead L, Fell JT, Collett JH. Development of a gastroretentive dosage
form. Eur. J. Pharm. Sci. 4 (Suppl.), 1996, S182.
29. Kawashima Y, Niwa T, Takeuchi H, Hino T, Itoh Y. Hollow microspheres for
use as a floating controlled drug delivery system in the stomach. J. Pharm. Sci.
81, 1992, 135-140.
227 References
30. Rubinstein A, Friend DR. Specific delivery to the gastrointestinal tract, In Domb
AJ (Ed.) Polymeric site specific pharmacotherapy, Wiley, Chichester, 1994,
282-283.
31. Stockwell AF, Davis SS, walker SE. In vitro evaluation of alginate gel system as
sustained release drug delivery system. J Control Release. 3, 1986, 167-175.
32. Klausner EA, Lavy E, Stepensky D, Friedman M, Hoffman A. Novel
gastroretentive dosage form: evaluation of gastroretentivity and its effect on
riboflavin absorption in dogs. Pharm. Res. 19, 2002, 1516-1523.
33. Moes AJ. Gastroretentive Dosage forms. Crit. Rev. Ther. Drug Carrier Syst. 10,
1993, 143-195.
34. Bechgaard H, Ladefoged K. Distribution of pellets in the gastrointestinal tract.
The influence on transit time exerted by the density or diameter of pellets. J.
Pharm. Pharmacol. 30, 1978, 690-692.
35. Wong P S L. Dong L C Edgren D E, Theeuwes RGardner P I. Jao F & Wan J J.
Prolonged release active agent dosage form adapted for gastric retention. US Pat
6120803, September 19, 2000.
36. El-Kamel A H, Sokar M S, Gamal S S A & Naggar V R. Preparation and
evaluation of ketoproten floating oral delivery system, hit J Pharm, 220, 2001,
13-21.
37. Moes A, Oth M, Franz M, Timmcrmans J. The bilayer floating capsule: a
stomach-directed drug delivery system for misoprostol, Pharm Res, 9, 1992,
298-302.
38. Kolter et al. Active ingredient containing floating forms comprising polyvinyl
acetate and polyvinyl pyrrolidone, their use and production. US pat 6, 635, 279.
228 References
39. Watanabe K, Machida Y, Takayama K, Iwata M & Nagai T. Preparation and
evaluation of intragastric floating tablet having pH independent buoyancy and
sustained release property, Arch Pract Pharm, 53, 1993, 1-7.
40. Umamaheshwari R B, Jain S & Jain N K. A new approach in gastroretentive
drug delivery system using cholestyramine, Drug Deliv, 10, 2003, 151 -160.
41. Timmermans J, Moes AJ. How well does floating dosage forms float. Int J
Pharm. 62, 1990, 207-16.
42. Whitehead L, Fell JT, Collett JH, Sharma HL, Smith AM. Floating dosage
forms: An In vivo study demonstrating prolonged gastric retention. J Control
Release. 55, 1998, 3-12.
43. Mojaverian P, Vlasses PH, Kellner PE, Rocci Jr ML. Effects of gender, posture,
and age on gastric residence time of an indigestible solid: Pharmaceutical
considerations. Pharm. Res. 10, 1988, 639-44.
44. Gansbeke BV, Timmermans J, Schoutens A, Moes AJ. Intragastric positioning
of two concurrently ingested pharmaceutical matrix dosage forms. Nucl Med
Biol. 18, 1991, 711-18.
45. Timmermans J, Moes AJ. Factors controlling the buoyancy and gastric retention
capabilities of floating matrix capsules: New data for reconsidering the
controversy. J Pharm Sci. 83, 1994, 18-24.
46. Babu VBM, Khar RK. In vitro and In vivo studies of sustained release floating
dosage forms containing salbutamol sulphate. Pharmazie. 45, 1990, 268-270.
47. Hetal N Kikani, A Thesis on, Floating Drug Delivery System, The North
Gujarat University, Patan, 2001, 11-12.
229 References
48. Singh BN, Kim KH. Floating drug delivery systems: an approach to oral
controlled drug delivery via gastric retention. J Control Release, 63, 2000, 235-
259.
49. Fell J T, Whitehead L, Collet H. Prolonged gastric retention using floating
dosage forms, Pharm Technol. 24(3), 2000, 82-90.
50. Menon A, Ritschel WA , Sakr A. Development and evaluation of a monolithic
floating dosage form for furosemide. J Pharm Sci. 83, 1994, 239-245.
51. Klausner EA, Eyal S, Lavy E, Friedman M, Hoffman A. Novel Levodopa
gastroretentive dosage form: In vivo evaluation in dogs. J. Controlled release.
88, 2003, 117-126.
52. Amnon Hoffman, David Stepensky, Eran Lavy, et al., Pharmacokinetic and
pharmacodynamic aspects of gastroretentive dosage forms, International Journal
of Pharmaceutics 277, 2004, 141–153.
53. Hoffman A. Pharmacodynamic aspects of sustained release preparation. Adv.
Drug Deliv. Rev. 33, 1998, 185-199.
54. R Garg and GD Gupta, Progress in Controlled Gastroretentive Delivery
Systems, Tropical Journal of Pharmaceutical Research, 7(3), 2008, 1055-1066.
55. Bakker A J, De Winter L M, Fabiano S, Inventors; Oral sustained release
formulation of tedisamil with gastric retention properties. US Patent Appl
2006003003. Jan 2006.
56. British National Formulary. 52 ed. London: British Medical Association and
Royal Pharmaceutical Society of Great Britain, 2006.
57. Drug profile of Famotidine from "http://en.wikipedia.org/wiki/Famotidine"
[Accessed: 05/04/2008].
230 References
58. Debas H. T, Mullholland M. W. New horizons in the pharmacologic
management of peptic ulceration. Am J Surgery. 151(3), 1986, 422-430.
59. Goodman and Gilmans – The pharmacological basis of therapeutics. 11th ed.,
McGraw Hill medical publishing division: New York, 2006, 1866.
60. Murakami H, Sun-Wada G.H, Matsumoto M, Nishi T, Wada Y, Futai M.
Human histamine H2 receptor gene: multiple transcription initiation and tissue-
specific expression. FEBS Lett. 451(3), 1999, 327-31.
61. Raymond C Rowe, Paul J Sheskey, Sian C Owen, Handbook of Pharmaceutical
Excipients. 5th ed., Pharmaceutical Press: London; 2006. 111-115, 346-349,
120-123, 315-317, 821-823.
62. Raymond C Rowe, Paul J Sheskey, Sian C Owen, Handbook of Pharmaceutical
Excipients. 5th ed., Pharmaceutical Press: London; 2006. 159-162.
63. A. Streubel, J. Siepmann and R. Bodmeier. Floating matrix tablets based on low
density foam powder: effects of formulation and processing parameters on drug
release, European Journal of Pharmaceutical Sciences, 18(1), 2003, 37-45.
64. Mirchandani HL, Chien YW, Bruce PD, Senshang L, Shoufeng L. Effect of
HPMC and carbopol on the release and floating properties of gastric floating
drug delivery system using factorial design. Int J Pharm., 253, 2003, 13-22.
65. Ozdemir N, Ordu S, Ozkan Y, Studies of floating dosage forms of furosemide:
In vitro and In vivo evaluations of bilayer tablet formulations, Drug Dev Ind
Pharm. 26(8), 2000, 857-66.
66. Sheth P R & Tossounian J. The hydrodynamically balanced system (HBSE): A
novel drug delivery system for oral use, Drug Dev bid Pharrn, 10, 1984, 313-
339.
231 References
67. Ingani H M, Timmermans J & Moes A J. Conception and In vivo investigation
of peroral sustained release floating dosage forms with enhanced gastrointestinal
transit, Int J Pharm. 35, 1987, 157-164.
68. Agyilirah GA, Green M, Ducret R. Evaluation of the gastric retention properties
of a cross-linked polymer coated tablet versus those of a non-disintegrating
tablets. Int J Pharm., 75, 1991, 241-247.
69. Hilton, A. K. Deasy, P. B. In vitro and In vivo evaluation of an oral sustained
Release floating dosage form of amoxicillin trihydrate. Int. J. Pharm. 86, 1992,
79‐88.
70. Subhash Desai, Sanford Bolton. A Floating Controlled-Release Drug Delivery
System: In vitro-In vivo Evaluation, Pharmaceutical Research, 10(9), 1993,
1321-1325.
71. A. Menon, W. Ritschel and A. Sakr, Development and evaluation of a
monolithic floating dosage form for furosemide. J. Pharm. Sci. 83, 1994, 239–
245.
72. J. Timmermans and A. J. Moes. Factors controlling the buoyancy and gastric
retention capabilities of floating matrix capsules: new data for reconsidering the
controversy, J. Pharm. Sci., 83, 1994, 8–24.
73. Libo Yang a, Jamshid Eshraghi b and Reza Fassihi. Zero-order release kinetics
from a self-correcting floatable asymmetric configuration drug delivery system.
J. Pharm. Sci. 85, 1996, 170–173.
74. Deshpande A.A., Shah N.H., Rhodes C.T., Malick. W. Development of a novel
controlled-release system for gastric retention. Pharm. Res. 14, 1997, 815-819.
75. Chen, G.L. Hao, W.H. In vitro performance of floating sustained-release capsule
of verapamil, Drug Dev. Ind. Pharm. 24, 1998, 1067–1072.
232 References
76. I. Krogel, R. Bodmeier. Floating or pulsatile drug delivery systems based on
coated effervescent cores, Int. J. Pharm. 187 (2), 1999, 175-184.
77. Wei Z, Yu Z, Bi D. Design and evaluation of a two-layer floating tablet for
gastric retention using cisapride as a model drug. Drug Dev Ind Pharm, 27,
2001, 469-74.
78. Rosa M, Zia H, Rhodes T. Dosing and testing In vitro of a bioadhesive and
floating drug delivery system for oral application, Int J Pharm 105, 1994, 65-70.
79. Franz M R, Oth M P, Sustained release, bilayer buoyant dosage form, US Pal 5,
August 3, 1993, 232, 704.
80. Dennis A, Timminis P, Lel K. Buoyant controlled release powder formulation.
US patent 5 December 8, 1992, 169, 638.
81. Mitra S B, Sustained release oral medicinal delivery device, US Pat 4, May 29,
1984, 451.
82. Thanoo BC, Sunny MC, Jayakrishnan A. Oral sustained release drug delivery
systems using polycarbonate microspheres capable of floating on the gastric
fluids. J Pharm Pharmacol. 45, 1993, 21-24.
83. Ichikawa M, Watanabe S, Miyake Y. A new multiple unit oral floating dosage
system. I: Preparation and In vitro evaluation of floating and sustained-release
kinetics. J Pharm Sci. 80, 1991, 1062-1066.
84. Atyabi F, Sharma HL, Mohammed HAH, Fell JT. In vivo evaluation of a novel
gastro retentive formulation based on ion exchange resins. J Control Release.
42, 1996, 105-113.
85. Ichikawa M, Watanabe S, Miyake Y. A new multiple-unit oral floating dosage
system. II: In vivo evaluation of floating and sustained-release characteristics
233 References
with para amino benzoic acid and isosorbide di nitrate as model drugs. J Pharm
Sci. 80, 1991, 1153-1156.
86. Whitehead L, Fell JT, Collett JH, Sharma HL, Smith A. In vivo study
demonstrating prolonged gastric retention. J Control Release. 55, 1998, 3-12.
87. Iannuccelli, V., Coppi, G., Sansone, R., Ferolla, G. Air compartment multiple-
unit system for prolonged gastric residence.Part II. In vivo evaluation. Int J
Pharm, 174, 1998, 55-62.
88. Kawashima Y, Niwa T, Takeuchi H, Hino T, Ito Y. Preparation of multiple unit
hollow microspheres (microballoons) with acrylic resins containing tranilast and
their drug release characteristics (In vivo). J Control Release. 16, 1991, 279-290.
89. El-Kamel AH, Sokar MS, Al Gamal SS, Naggar VF. Preparation and evaluation
of ketoprofen floating oral drug delivery system. Int J Pharm. 220, 2001, 13-21.
90. Nakamichi K, Yasuura H, Fukui H, Oka M, Izumi S. Evaluation of a floating
dosage form of nicardipine hydrochloride and hydroxypropyl methylcellulose
acetate succinate prepared using a twin-screw extruder, Int J Pharm. May 7
218(1-2), 2001, 103-12.
91. Bulgarelli E, Forni F, Bernabei MT. Effect of matrix composition and process
conditions on casein gelatin beads floating properties. Int J Pharm. 198, 2000,
157-165.
92. Whitehead L, Collett JH, Fell JT. Amoxycillin release from a floating dosage
form based on alginates. Int J Pharm. 210, 2000, 45-49.
93. Yasunori Sato, Yoshiaki Kawashima, Hirofumi Takeuchi, Hiromitsu
Yamamoto. In vitro evaluation of floating and drug releasing behaviour of
hollow microspheres (micro balloons) prepared by emulsion solvent diffusion
234 References
method. European journal of pharmaceutics and biopharmaceutics, 57, 2004,
235– 243.
94. Timmermans J, Andre JM. Factors controlling the buoyancy and gastric
retention capabilities of floating matrix capsules: new data for reconsidering the
controversy. J Pharm Sci. 83, 1994, 18-24.
95. Choi BY, Park HJ, Hwang SJ, Park JB. Preparation of alginate beads for
floating drug delivery: effects of CO2 gas forming agents. Int J Pharm. 239,
2002, 81-91.
96. Li S, Lin S, Daggy BP, Mirchandani HL, Chien TW. Effect of formulation
variables on the floating properties of gastric floating drug delivery system.
Drug Dev Ind Pharm. 28, 2002, 783-793.
97. Penners G, Lustig K, Jorg PVG. Expandable pharmaceutical forms. US patent 5
July 29, 1997, 651, 985.
98. Fassihi R, Yang L. Controlled release drug delivery systems. US patent 5 July
21, 1998, 783, 212.
99. Talwar N, Sen H, Staniforth JN. Orally administered controlled drug delivery
system providing temporal and spatial control. US patent 6 July 17, 2001, 261
601.
100. Baumgartner S, Kristel J, Vreer F, Vodopivec P, Zorko B. Optimization of
floating matrix tablets and evaluation of their gastric residence time. Int J
Pharm. 195, 2000, 125-135.
101. Nur AO, Zhang JS. Captopril floating and/or bioadhesive tablets: design and
release kinetics. Drug Dev Ind Pharm. 26, 2000, 965-969.
235 References
102. Asmussen B, Cremer K, Hoffmann HR, Ludwig K, Roreger M. Expandable
gastroretentive therapeutic system with controlled active substance release in
gastrointestinal tract. US patent 6 September 18, 2001, 290, 989.
103. Illum L, Ping H. Gastroretentive controlled release microspheres for improved
drug delivery. US patent 6 March 27, 2001, 197, 207.
104. Ushomaru K, Nakachimi K, Saito H. Pharmaceutical preparations and a method
of manufacturing them. US patent 4. October 27, 1987, 702, 918.
105. Bolton S, Desai S. Floating sustained release therapeutic compositions. US
patent 4. March 21, 1989, 179, 814.
106. Spickett RGW, Vidal JLF, Escoi JC. Antacid preparation having prolonged
gastric residence. US patent 5. February 22, 1993, 288,506.
107. Wu W, Zhou Q, Zhang HB, Ma GD, Fu CD. Studies on nimodipine sustained
release tablet capable of floating on gastric fluids with prolonged gastric resident
time. Yao Xue Xue Bao. 32, 1997, 786-790.
108. Dave BS, Amin AF, Patel MM. Gastroretentive drug delivery system of
ranitidine hydrochloride: formulation and In vitro evaluation. AAPS Pharm Sci
Tech. 5, 2004, E34.
109. Reddy L, Murthy R. Floating dosage systems in drug delivery. Crit Rev Ther
Drug Carrier Syst. 19, 2002, 553-585.
110. Mahesh Chavanpatil, , Paras Jain, Sachin Chaudhari, Rajesh Shear and Pradeep
Vavia, Development of sustained release gastroretentive drug delivery system
for ofloxacin: In vitro and In vivo evaluation, International Journal of
Pharmaceutics, 304 (1-2), 2005, 178-184.
236 References
111. Wong PSL, Dong LC, Edgren DE, Theeuwes F. Prolonged release active agent
dosage form adapted for gastric retention. US patent 6. September 19, 2000,
120, 803.
112. Brijesh S Dave, Avani Amin F. Gastro retentive Drug Delivery System of
Ranitidine Hydrochloride: Formulation and In vitro Evaluation. AAPS Pharm
Sci Tech. 5(2), 2004, 34-40.
113. Dumpeti Janardhan, Meka Lingam. Formulation and In vitro Evaluation of
Gastro retentive Drug Delivery System for Ranitidine Hydrochloride.
International Journal of Pharmaceutical Sciences and Nanotechnology. 1(3),
2008, 272-232.
114. Alagusundaram M., Chengaiah B. Formulation and evaluation of mucoadhesive
buccal films of Ranitidine HCl. Int J Pharma Tech Res. 1(3), 2009, 557-563.
115. Dinesh Dhamecha, Amit A Rathi. Development and In vitro Evaluation of Oral
Floating Matrix Tablet Formulation of Ranitidine Hydrochloride. Research J.
Pharma. Dosage Forms and Tech. 1(1), 2009, 41-44.
116. Chavda H, Patel C. Chitosan superporous hydrogel composite-based floating
drug delivery system: A newer formulation approach. J Pharm Bioall Sci 2,
2010, 124-31.
117. Jaimini M, Rana A.C. Formulation and Evaluation of Famotidine Floating
Tablets. Current Drug Delivery. 4, 2007, 51-55.
118. Monica RP Rao, Girish S Sonar, Rachana R Mandsaurwale, Swapnila D
Vanshiv, Evaluation of effervescent floating matrix tablet formulations of
salbutamol sulfate using full factorial design, Asian Journal of Pharmaceutics,
3(1), 2009, 43-49.
237 References
119. Sauzet C, Claeys-Bruno M, Nicolas M, Kister J, Piccerelle P, Prinderre P. An
innovative floating gastro retentive dosage system: formulation and In vitro
evaluation, Int J Pharm. Aug 13;378(1-2), 2009, 23-29.
120. Ajit Kulkarni, Manish Bhatia. Development and evaluation of regioselective
bilayer floating floating tablets of Atenolol and Lovastatin, Iranian Journal of
Pharmaceutical Research, 8 (1), 2009, 15-25.
121. Ramesh bomma et al. Development and evaluation of gastroretentive
norfloxacin floating tablets, Acta Pharm. 59, 2009, 211–221.
122. Rajeev Garg and GD Gupta. Gastroretentive Floating Microspheres of
Silymarin: Preparation and In vitro Evaluation, Tropical Journal of
Pharmaceutical Research, February 9 (1), 2010, 59-66.
123. Ferdous Khan, Md. Et al. Preparation and In vitro Evaluation of Theophylline
Loaded Gastroretentive Floating Tablets of METHOCEL K4M, Dhaka Univ. J.
Pharm. Sci. 7(1), 2008, 65-70.
124. Shailesh T. Prajapati, Laxmanbhai D. Patel, Dasharath M. Patel, Gastric floating
matrix tablets: Design and optimization using combination of polymers, Acta
Pharm. 58, 2008, 221–229.
125. Goole J, Vanderbist F, Aruighi K. Development and evaluation of new multiple-
unit levodopa sustained-release floating dosage forms. Int J Pharm 334, 2007,
35-41.
126. Patel DM, Patel NM, Pandya NN, Jogani PD. Formulation and optimization of
carbamazepine floating tablets. Indian J Pharm Sci 69, 2007, 763-767.
127. Girish S. Sonar, Devendra K. Jain, Dhananjay M. More. Preparation and In vitro
evaluation of bilayer and floating bioadhesive tablets of rosiglitazone maleate,
Asian Journal of Pharmaceutical Sciences 2 (4), 2007, 161-169.
238 References
128. Jain SK, Agrawal GP, Jain NK. Evaluation of Porous Carrier-based Floating
Orlistat Microspheres for Gastric Delivery. AAPS PharmSciTech. 7(4), 2006,
90.
129. Gambhire MN, Ambade KW, Kurmi SD, Kadam VJ, Jadhav KR. Development
and In vitro Evaluation of an Oral Floating Matrix Tablet Formulation of
Diltiazem Hydrochloride. AAPS PharmSciTech. 8(3), 2007, 73.
130. Ziyaur Rahman, Design and evaluation of bilayer floating tablets of captopril,
Acta Pharm. 56, 2006, 49–57.
131. Jaleh Varshosaz, N Tavakoli, F Roozbahani, Formulation and In vitro
Characterization of Ciprofloxacin Floating and Bioadhesive Extended-Release
Tablets, Drug Delivery 13:44, 277-285.
132. Xiaoqiang Xu, Minije S, Feng Z, Yiqiao Hu. Floating matrix dosage form for
phenoporlamine hydrochloride based on gas forming agent: In vitro and In vivo
evaluation in healthy volunteers. Int J Pharm. 310, 2006, 139-145.
133. Ravindra S Dhumal, Samitkumar T Rajmane, Sanjay T Dhumal, Atmaram P
Pawar, Design and evaluation of bilayer floating tablets of cefuroxime axetil for
bimodal release, Journal of Scientific & Industrial Research Vol. 65, October
2006, 812-816.
134. Narendra C, Srinath MS, Babu G. Optimization of Bilayer Floating Tablet
Containing Metoprolol Tartrate as a Model Drug for Gastric Retention. AAPS
Pharm Sci Tech. 7(2), 2006, 34.
135. Wieseaw Sawicki, Rafal Lunio. Tableting of floating pellets with verapamil
hydrochloride: influence of type of tablet press, Acta Poloniae Pharmaceutica -
Drug Research, Vol. 67 No. 1, 2010, 103-106.
239 References
136. A. Streubel, J. Siepmann and R. Bodmeier. Floating matrix tablets based on low
density foam powder: effects of formulation and processing parameters on drug
release, European Journal of Pharmaceutical Sciences, 18(1), 2003, 37-45.
137. Nurten Özdemir and Sefika Ordu. Improvement of Dissolution Properties of
Furosemide by Complexation with β-Cyclodextrin, Drug Development and
Industrial Pharmacy, 24(1), 1998, 19-25.
138. Nathalie Rouge, et al. Comparative pharmacokinetic study of a floating
multiple-unit capsule, a high-density multiple-unit capsule and an immediate-
release tablet containing 25 mg atenolol, Pharmaceutica Acta Helvetiae, 73(2),
1998, 81-87.
139. R.F. Weska, J.M. Moura, L.M. Batista, J. Rizzi and L.A.A. Pinto. Optimization
of deacetylation in the production of chitosan from shrimp wastes: Use of
response surface methodology, Journal of Food Engineering, 80(3), 2007, 749-
753.
140. Harpreet K. Dhiman, Alok R. Ray and Amulya K. Panda. Characterization and
evaluation of chitosan matrix for In vitro growth of MCF-7 breast cancer cell
lines, Biomaterials, 25(21), 2004, 5147-5154 .
141. Rinaudo, M. Chitin and chitosan: Properties and applications, Progress in
Polymer Science, 31(7), 2006, 603-632.
142. V. R. Sinha , A. K. Singla , S. Wadhawan , R. Kaushik , R. Kumria , K. Bansal
and S. Dhawan. Chitosan microspheres as a potential carrier for drugs,
International Journal of Pharmaceutics, 274(1-2), 2004, 1-33.
143. Radi Hejazi and Mansoor Amiji. Chitosan-based gastrointestinal delivery
systems, Journal of Controlled Release, 89(2), 2003, 151-165.
240 References
144. Picker-Freyer KM, Brink D. Evaluation of Powder and Tableting Properties of
Chitosan. AAPS PharmSciTech. 7(3), 2006, 75.
145. Entsar S. Abdou, Khaled S.A. Nagy and Maher Z. Elsabee. Extraction and
characterization of chitin and chitosan from local sources, Bioresource
Technology, 99(5), 2008, 1359-1367.
146. Alaa Eldeen B. Yassin, Ibrahim A. Alsarra and Abdulah M. Al-Mohizea,
Chitosan Beads as a New Gastroretentive System of Verapamil, Sci Pharm. 74,
2006, 175–188.
147. I. C. E. Wesdorp, W. Dekker and H. P. M. Festen. Efficacy of famotidine 20 mg
twice a day versus 40 mg twice a day in the treatment of erosive or ulcerative
reflux esophagitis, Digestive Diseases and Sciences, 38(12), 2005, 2287-2293.
148. Ranitidine hydrochloride tablets, USP 150 mg and 300 mg, Available at:
http://www.medicineonline.com/drugs/R/3479/RANITIDINE-TABLETS-
USP.html [Accessed October 2008].
149. A. M. Umarunnisha, S. Palanichamy, M. Rajesh, S. Jeganath, A.
Thangathirupathi. Formulation and evaluation of matrix tablets of Famotidine
using hydrophilic polymer, Archives of Applied Science Research, 2(3), 2010,
212-220.
150. Yu-meng Wei and Ling Zhao. In vitro and In vivo evaluation of ranitidine
hydrochloride loaded hollow microspheres in rabbits, Archives of Pharmacal
Research, 31(10), 2008, 1369-1377.
151. Mohamed HG Dehghan Furquan N Khan. Gastroretentive Drug Delivery
Systems: A Patent Perspective, International Journal of Health Research, 2(1),
2009, 23-44.
241 References
152. Radi Hejazi and Mansoor Amiji. Chitosan-based gastrointestinal delivery
systems, Journal of Controlled Release, 89(2), 2003, 151-165.
153. J. Shaji, V. Jain, S. Lodha. Chitosan: A Novel Pharmaceutical Excipient,
International Journal of Pharmaceutical and Applied Sciences, 1 (1), 2010, 11-
28.
154. Qi Zhao Wanga, et al. Protonation constants of chitosan with different
molecular weight and degree of deacetylation, Carbohydrate Polymers, 65(2),
2006, 194-201.
155. Mao S, Shuai X, Unger F, Simon M, Bi D, Kissel T, The depolymerization of
chitosan: effects on physicochemical and biological properties, Int J Pharm.
281(1-2), 2004, 45-54.
156. Pradip Kumar Dutta, Joydeep Dutta, V S Tripathi. Chitin and chitosan:
Chemistry, properties and applications, Journal of Scientific & Industrial
Research 63, 2004, 20-31.
157. F.A. Al Sagheera, M.A. Al-Sughayerb, S. Muslima, M.Z. Elsabee. Extraction
and characterization of chitin and chitosan from marine sources in Arabian Gulf,
Carbohydrate Polymers. 77(2), 2009, 410-419.
158. Xuan Jiang, Lirong Chen, Wei Zhong. A new linear potentiometric titration
method for the determination of deacetylation degree of chitosan, Carbohydrate
Polymers. 54(4), 2003, 457-463.
159. Harpreet K. Dhiman, Alok R. Raya, Amulya K. Panda. Characterization and
evaluation of chitosan matrix for In vitro growth of MCF-7 breast cancer cell
lines, Biomaterials. 25(21), September 2004, 5147-5154.
160. Indian Pharmacopoeia. The Controller of Publication. Delhi, 2, 1996, 735.
242 References
161. Qing Sheng Zhao et al. Preparation of alginate coated chitosan hydrogel beads
by thermosensitive internal gelation technique. Journal of Sol-Gel Science and
Technology. 54(2), 2010, 232-237.
162. Reddy NR, Prabhavathi K, Bhaskar Reddy YV, Chakravarthy IE. A new
spectrophotometric determination of famotidine from tablets. Indian J Pharm Sci
68, 2006, 645-647.
163. Trivedi, N.D., U.N. Trivedi, M.M. Patel, J.K. Patel and A. Bhandari. Preparation
and evaluation of floating matrix tablet of ranitidine. Am. J. Drug Discovery
Develop. 1, 2011, 8-23.
164. P. Narayana Raju, K. Prakash, M. Lakshmi Narasu. Compatibility Study of
Lamivudine with Various Cellulose Polymers, E-Journal of Chemistry, 6(S1),
2009, S17-S20.
165. B.Mandal, K. S.Alexander, A. T.Riga. Evaluation of the drug-polymer
interaction in calcium alginate beads containing diflunisal. 65(2), 2010, 106-
109.
166. G. Bruni, L. Amici, V. Berbenni, A. Marini, A. Orlandi. Drug-Excipient
Compatibility Studies. Search of interaction indicators, Journal of Thermal
Analysis and Calorimetry. 68(2), 2004, 561-573.
167. S. T. Prajapati, L. D. Patel, D. M. Patel. Studies on Formulation and In vitro
Evaluation of Floating Matrix Tablets of Domperidone. Indian J Pharm Sci.
71(1), 2009, 19–23.
168. Anilkumar J. Shinde , Manojkumar S. Patil, Harinath N. More. Formulation and
Evaluation of an Oral Floating Tablet of Cephalexin. Indian J.Pharm. Educ. Res.
44(3), 2010, 243-252.
243 References
169. Sanjay S. Patel, S. Ray, R. S. Thakur. Formulation and evaluation of floating
drug delivery system containing clarithromycin for helicobacter pylori, Acta
Poloniae Pharmaceutica - Drug Research, 63(1), 2006, 53-61.
170. Havaldar VD, Kulkarni AS, Dias RJ, Aloorkar NH, Mali KK. Floating matrix
tablets of atenolol: Formulation and In vitro evaluation. Asian J Pharm, 3, 2009,
286-291.
171. Ravi Kumar, M. B. Patil, Sachin R. Patil, Mahesh S. Paschapur. Formulation
and Evaluation of Effervescent Floating Tablet of Famotidine, International
Journal of PharmTech Research, 1(3), 2009, 754-763.
172. Mukesh C. Gohel, Pavak R. Mehta, Rikita K. Dave, Nehal H. Bariya. A More
Relevant Dissolution Method for Evaluation of Floating Drug Delivery System,
Dissolution technologies, 2004, 22-25.
173. Ritger PL, Peppas NA. A simple equation for the description of solute release,
II: Fickian and anomalous release from swellable devices. J Control Release. 5,
1987, 37-42.
174. M. Harris Shoaib, Jaweria Tazeen, Hamid A. Merchant, Rabia Ismail Yousuf.
Evaluation of drug release kinetics from ibuprofen matrix tablets using HPMC,
Pak. J. Pharm. Sci., 19(2), 2006, 119-124.
175. Carstensen, J.T. "Stability and Dating of Solid Dosage Forms," Pharmaceutics
of Solids and Solid Dosage Forms, Wiley-Interscience, 1977, 182-185.
176. Hsin-ya Lee, Pao-chu Wu, Yung-jin Lee, Stab: An R package for drug stability
data analysis, 100(2), 2010, 140-148.
177. Q1E Evaluation of Stability Data, Guidance for Industry, ICH June 2004, 1-11.
178. Shah SS, Pandya SJ, Waghulade MK. Development and investigation of gastro
retentive dosage form of weakly basic drug. Asian J Pharm, 4, 2010, 11-6.
244 References
179. Baumgartner S., Julijana K., Franc V., Polona V. and Bojon J. Optimization of
floating matrix tablets and evaluation of their gastric residence time, Int. J.
Pharm., 195, 2000, 125-135.
180. Koresmeyer R W, Gurny R, Doelkar E, Buri P, Peppas N A. Mechanisms of sol
ute release from porous hydrophilic polymer. Int J Pharm 15, 1983, 23‐25.
181. N. Helali, F. Darghouth and L. Monser. RP-HPLC Determination of Famotidine
and its Potential Impurities in Pharmaceuticals, 60(7-8), 2004, 455-460.
182. T C Dowling, R F Frye. Determination of famotidine in human plasma and urine
by high-performance liquid chromatography, J Chromatogr B Biomed Sci Appl.
732(1), 1999, 239-243.
183. Salem, M. S., Gharaibeh, A. M., Alkaysi, H. N. and Badwan, A. High-
Performance Liquid Chromatographic analysis of ranitidine in plasma and urine.
Journal of Clinical Pharmacy and Therapeutics, 13, 1988, 351–357.
184. V. Das Gupta. Quantitation of Ranitidine Hydrochloride in Tablets and
Injections Using High-Performance Liquid Chromatography, Drug
Development and Industrial Pharmacy - 14(12), 1998, 1647-1655.
185. D. Harries., H. L. Sharma. GI transit of potential bioadhesive formulations in
man: A scintigraphic study. J. Control. Release, 12, 1990, 45-53.
186. J. Timmermans, V. B. Gansbeke, A. J. Moes. Assessing by gamma scintigraphy
the In vivo buoyancy of dosage forms having known size and floating force
profiles as a function of time. Vol I. Proceedings of the 5th International
Conference on Pharmacy Technology. Paris, France: APGI, 1989: 42-51.
187. V F Smolen. Bioavailability and Pharmacokinetic Analysis of Drug Responding
Systems, Annual Review of Pharmacology and Toxicology, 18, 1978, 495-522.
245 References
188. Ylitalo, P., Hinkka, H, Neuvonen, P.J. Effect of exercise on the serum level and
urinary excretion of tetracycline, doxycyclineand sulphamethizole. Eur. J. din.
Pharmac, 12, 1977, 367-373.
189. Sajid Bashir, Mohammad Jamshaid, Bashir Ahmad, Javeid Iqbal,
Pharmacokinetics of ciprofloxacin in normal rabbits and changes observed in
induced dehydrated state, Pak. J. Pharm. Sci., 21(3), 2008, 225-229.
190. Oncology Tools: Dose Calculator, US Food and Drug Administration, Available
online at http://www.accessdata.fda.gov/scripts/cder/onctools/animalquery.cfm
[Accessed on: 14/04/2008].
191. Blood collection and administration of fluids and drugs (rabbit), Available
online at http://research.uiowa.edu/animal/?get=rbt_tech [Accessed on:
04/04/2008].
192. Seham A. Elkheshen, Alaa Eldeen, B. Yassin, Saleh Alsuwayeh, Fayza A.
Alkhaled. In vitro and In vivo evaluation of Floating controlled release dosage
forms of verapamil hydrochloride, Pharm. Ind. 66, Nr. 11, 2004, 1064-1372.
193. Guidance for Industry, Statistical approaches to establishing bioequivalence, US
FDA, Center for drug evaluation and research, 2001, 1-45.
194. Hsin-ya Lee and Yung-jin Lee, Bear: The data analysis tool for average
bioequivalence (ABE) and bioavailability (BA) in R Available online at
http://pkpd.kmu.edu.tw/bear/ [Accessed on: 15/07/2010].
195. Nattee Sirisuth, Natalie D. Eddington. In vitro-In vivo Correlation Definitions
and Regulatory Guidance, International Journal of Generic Drugs, Available
online at http://www.locumusa.com [Accessed on: 07/06/2009].
196. Jaber Emami, In vitro - In vivo Correlation: From Theory to Applications, J
Pharm Pharmaceut Sci 9(2), 2006, 169-189.
246 References
197. Hsin-ya Lee and Yung-jin Lee, IVIVC for R - A Tool for ―In vitro-In vivo
Correlation" Exploration with R Available at http://pkpd.kmu.edu.tw/ivivc/
[Accessed on: 15/07/2010].
198. Selye, H. A Syndrome produced by diverse nocuous agents. Nature 138, 1936,
32.
199. Hanson, H.M, Brodie, D.A. Use of the restrained rat technique for study of the
antiulcer effect of drugs, J. Appl. Physiol, 15, 1960, 291-294.
200. Chun-Chao Chang, Sheng-Hsuan Chen, Gi-Shih Lien, Horng-Yuan Lou, Ching-
Ruey Hsieh, Chia-Lang Fang, Shiann Pan. Eradication of Helicobacter pylori
significantly reduced gastric damage in nonsteroidal anti-inflammatory drug-
treated Mongolian gerbils, World J Gastroenterol, 11(1), 2005, 104-108.
201. Piper DW, Stiel DD. Pathogenesis of chronic peptic ulcer DW, Stiel DD.
Pathogenesis of chronic peptic ulcer, current thinking and clinical implications.
Med Prog 2, 1986, 7-10.